Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
13.07
+0.38 (2.96%)
At close: Oct 9, 2026, 4:00 PM EDT
13.12
+0.05 (0.42%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Bioventus Revenue
Bioventus had revenue of $153.21M in the quarter ending June 27, 2026, with 3.76% growth. This brings the company's revenue in the last twelve months to $581.85M, up 3.14% year-over-year. In the year 2025, Bioventus had annual revenue of $568.09M, down -0.91%. That makes Bioventus the 10,365th largest company in the world by revenue and 2,198th in the United States.
Revenue (ttm)
$581.85M
Revenue Growth
+3.14%
P/S Ratio
1.89
Revenue / Employee
$612,472
Employees
950
Market Cap
1.10B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 568.09M | -5.19M | -0.91% |
| Dec 31, 2024 | 573.28M | 60.94M | 11.89% |
| Dec 31, 2023 | 512.35M | 228.00K | 0.04% |
| Dec 31, 2022 | 512.12M | 81.22M | 18.85% |
| Dec 31, 2021 | 430.90M | 109.74M | 34.17% |
| Dec 31, 2020 | 321.16M | -18.98M | -5.58% |
| Dec 31, 2019 | 340.14M | 20.96M | 6.57% |
| Dec 31, 2018 | 319.18M | 65.53M | 25.83% |
| Dec 31, 2015 | 253.65M | 10.76M | 4.43% |
| Dec 31, 2014 | 242.89M | 10.52M | 4.53% |
| Dec 31, 2013 | 232.38M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| QuidelOrtho | 2.67B |
| Enovis | 2.30B |
| Integra LifeSciences Holdings | 1.65B |
| CONMED | 1.37B |
| Lumexa Imaging Holdings | 1.04B |
| Tandem Diabetes Care | 1.04B |
| Artivion | 471.47M |
| PROCEPT BioRobotics | 337.34M |
BVS News
- 7 weeks ago - Bioventus price target raised to $19 from $15 at Canaccord - TheFly
- 2 months ago - Bioventus price target raised to $18 from $16 at Craig-Hallum - TheFly
- 2 months ago - Bioventus price target raised to $18 from $14 at Barrington - TheFly
- 2 months ago - Bioventus reports Q2 EPS 22c, consensus 22c - TheFly
- 2 months ago - Bioventus backs FY26 adjusted EPS view 75c-79c, consensus 78c - TheFly
- 2 months ago - Bioventus initiates review of strategic alternatives - TheFly
- 2 months ago - Bioventus Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Bioventus Earnings release: Q2 2026 - Filings